IDO1 and cancer: Research on IDO1 activity in cancer has focused predominantly on the concept that TRP depletion is the main regulatory node of T cell suppression, which spurred the development of IDO1 inhibitors and their testing in clinical cancer settings (Labadie et al., 2019).